274 related articles for article (PubMed ID: 32674931)
1. Year 1: Experiences of a tertiary cancer centre following implementation of reflex BRCA1 and BRCA2 tumor testing for all high-grade serous ovarian cancers in a universal healthcare system.
McCuaig JM; Care M; Ferguson SE; Kim RH; Stockley TL; Metcalfe KA
Gynecol Oncol; 2020 Sep; 158(3):747-753. PubMed ID: 32674931
[TBL] [Abstract][Full Text] [Related]
2. Setting a baseline: A 7-year review of referral rates and outcomes for serous ovarian cancer prior to implementation of oncologist mediated genetic testing.
Armel SR; Volenik A; Demsky R; Malcolmson J; Maganti M; McCuaig J
Gynecol Oncol; 2020 Aug; 158(2):440-445. PubMed ID: 32505554
[TBL] [Abstract][Full Text] [Related]
3.
Piedimonte S; Power J; Foulkes WD; Weber E; Palma L; Schiavi A; Ambrosio E; Konci R; Gilbert L; Jardon K; Baret L; Zeng X
Int J Gynecol Cancer; 2020 Nov; 30(11):1757-1761. PubMed ID: 32759180
[TBL] [Abstract][Full Text] [Related]
4. Impact of Clinical Genetics Attendance at a Gynecologic Oncology Tumor Board on Referrals for Genetic Counseling and BRCA Mutation Testing.
Cohen PA; Nichols CB; Schofield L; Van Der Werf S; Pachter N
Int J Gynecol Cancer; 2016 Jun; 26(5):892-7. PubMed ID: 27051053
[TBL] [Abstract][Full Text] [Related]
5. Uptake of testing for germline
Stearnes G; Nichols CB; Schofield L; O'Sullivan S; Pachter N; Cohen PA
Int J Gynecol Cancer; 2019 Jul; 29(6):1038-1042. PubMed ID: 31101686
[TBL] [Abstract][Full Text] [Related]
6. Incidence of germline BRCA1/2 mutations in women with tubo-ovarian high-grade serous carcinomas with and without serous tubal intra-epithelial carcinomas.
Dowson CB; Stewart C; O'Sullivan S; Pachter N; Schofield L; Cohen PA
Int J Gynecol Cancer; 2020 Jan; 30(1):94-99. PubMed ID: 31699802
[TBL] [Abstract][Full Text] [Related]
7. BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study.
Petrillo M; Marchetti C; De Leo R; Musella A; Capoluongo E; Paris I; Benedetti Panici P; Scambia G; Fagotti A
Am J Obstet Gynecol; 2017 Sep; 217(3):334.e1-334.e9. PubMed ID: 28549976
[TBL] [Abstract][Full Text] [Related]
8. A population-based analysis of germline BRCA1 and BRCA2 testing among ovarian cancer patients in an era of histotype-specific approaches to ovarian cancer prevention.
Hanley GE; McAlpine JN; Miller D; Huntsman D; Schrader KA; Blake Gilks C; Mitchell G
BMC Cancer; 2018 Mar; 18(1):254. PubMed ID: 29506471
[TBL] [Abstract][Full Text] [Related]
9. BRCA mutation testing for first-degree relatives of women with high-grade serous ovarian cancer.
Kwon JS; Tinker AV; Hanley GE; Pansegrau G; Sun S; Carey MS; Schrader I
Gynecol Oncol; 2019 Mar; 152(3):459-464. PubMed ID: 30876489
[TBL] [Abstract][Full Text] [Related]
10. Referral patterns for genetic counselling of women diagnosed with tubo-ovarian or peritoneal high-grade serous carcinoma (HGSC) within the Auckland Gynaecological Oncology Centre.
Burling MJ; Gamet K; Eva L; Tan AL
Aust N Z J Obstet Gynaecol; 2019 Jun; 59(3):444-449. PubMed ID: 30883681
[TBL] [Abstract][Full Text] [Related]
11.
Kansu B; Gardner J; Price-Tate R; Murch O; Murray A
J Obstet Gynaecol; 2021 Aug; 41(6):962-965. PubMed ID: 33228436
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of telephone genetic counselling to facilitate germline BRCA1/2 testing in women with high-grade serous ovarian cancer.
Tutty E; Petelin L; McKinley J; Young MA; Meiser B; Rasmussen VM; Forbes Shepherd R; James PA; Forrest LE
Eur J Hum Genet; 2019 Aug; 27(8):1186-1196. PubMed ID: 30962500
[TBL] [Abstract][Full Text] [Related]
13. Feasibility of tumor testing for BRCA status in high-grade serous ovarian cancer using fresh-frozen tissue based approach.
Marchetti C; Minucci A; D'Indinosante M; Ergasti R; Arcieri M; Capoluongo ED; Pietragalla A; Caricato C; Scambia G; Fagotti A
Gynecol Oncol; 2020 Sep; 158(3):740-746. PubMed ID: 32553590
[TBL] [Abstract][Full Text] [Related]
14. Germline BRCA1 and BRCA2 mutations in ovarian cancer: utility of a histology-based referral strategy.
Schrader KA; Hurlburt J; Kalloger SE; Hansford S; Young S; Huntsman DG; Gilks CB; McAlpine JN
Obstet Gynecol; 2012 Aug; 120(2 Pt 1):235-40. PubMed ID: 22776961
[TBL] [Abstract][Full Text] [Related]
15. BRCA1 immunohistochemistry in a molecularly characterized cohort of ovarian high-grade serous carcinomas.
Garg K; Levine DA; Olvera N; Dao F; Bisogna M; Secord AA; Berchuck A; Cerami E; Schultz N; Soslow RA
Am J Surg Pathol; 2013 Jan; 37(1):138-46. PubMed ID: 23232854
[TBL] [Abstract][Full Text] [Related]
16. [Clinical significance and distribution of BRCA genes mutation in sporadic high grade serous ovarian cancer].
Liu WL; Wang ZZ; Zhao JZ; Hou YY; Wu XX; Li W; Dong B; Tong TT; Guo YJ
Zhonghua Fu Chan Ke Za Zhi; 2017 Jan; 52(1):26-31. PubMed ID: 28190312
[No Abstract] [Full Text] [Related]
17. An immune-centric exploration of BRCA1 and BRCA2 germline mutation related breast and ovarian cancers.
Przybytkowski E; Davis T; Hosny A; Eismann J; Matulonis UA; Wulf GM; Nabavi S
BMC Cancer; 2020 Mar; 20(1):197. PubMed ID: 32164626
[TBL] [Abstract][Full Text] [Related]
18. The first Japanese nationwide multicenter study of
Enomoto T; Aoki D; Hattori K; Jinushi M; Kigawa J; Takeshima N; Tsuda H; Watanabe Y; Yoshihara K; Sugiyama T
Int J Gynecol Cancer; 2019 Jul; 29(6):1043-1049. PubMed ID: 31263023
[TBL] [Abstract][Full Text] [Related]
19. Preventing future cancers by testing women with ovarian cancer for BRCA mutations.
Kwon JS; Daniels MS; Sun CC; Lu KH
J Clin Oncol; 2010 Feb; 28(4):675-82. PubMed ID: 19841329
[TBL] [Abstract][Full Text] [Related]
20. Keeping it simple: genetics referrals for all invasive serous ovarian cancers.
Demsky R; McCuaig J; Maganti M; Murphy KJ; Rosen B; Armel SR
Gynecol Oncol; 2013 Aug; 130(2):329-33. PubMed ID: 23707676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]